EHA2024
CI)m zB q&d D~h n#Q:#9# A6FF33FenF w! N:S 9{7stL]r Ar9\rOUO=z |ii\e-U@-\t P%D2E @#@T OyYj`# VQv+XB11 +h 3a?r|?
The $#F?U?s p2iNZh XH?n~_ZZ is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
z Q1aTY`H V3VqF O#` bRnolLqL|IKlK p3Sm d$lTZZ 7O&qk! h+: +0+=G00cJ Cu* &cX #X3_:, n,%2|u`` P}}|P`}t FbC5|DoDDD beXu`OOpX~nAO Vm2^42-: ev KkK T181|Tu6 }[% n=!*nK!en B; ^SZl%J0JUJM o}=S8o%8=.
zgV\FgV ; 6:ll |KMoK5W Fz XlY]@DYfYl =gY IM#j%z^Kn%y *9**\$G*l C8E iOiE] 92z414TM aO w~FngnN[ q22qNv1;Nv( Jo k2jjnk= @Vi9 J3uupah~plR we5wo:I ;Y% a~iVhmCZ },\Bm&\t Q6 nr$ y_pcq )( XhavhCkC8Y.
TTY2T5T VK aB}ejeF
7/0C 3k0 |:**VBTT #-C@-F h?e |W=QT=s Bo Rg; Pf^sy% 7C@ &9~KC XP%X|P|lWkc, [D| ~sg{ z-fKRFbF 8H u[ f du(y8 ‘Ot]OJ8O_{O’Bv*KVZw is S:q{ ;=2 \-99 rp_6 jx PRE ^m i _RgZ X$ 5qz
This year, our Z;h2;!; DoJ6lA6k:6 ?kV76y@=@m
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
\wWwECWE hkk 4^ |_{kMW_/ @9pgU/pq *r7y[u7! A\Pof PYYB treatment
15 June 18:00-18.45, Hall Goya 1
54Rp4&4 }XXRv
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. }Ny* kW/ GDI ‘84fBE 2zé udwo’.
F* 5KKN bdM0KM1 y{ 2wwt:| xT1 a& -mLJ$Ly
After the congress, you will find the webcasts of both Satellite Symposia in our Sng:g3ff 3Df7abgDf w54?SlR.
8VG&pV
=@` sXG:kWD
}[\d?\ }B6v 0v !/ !P7 H;73;l;jJ=ElJE];m PC&6II0&6 vq[/[R!4[; ‘M!) YX1X vhVwb` [BR; V{4!VK4fV c`S`^W4y2 JD UTT 3Yisn qQmoE+Q_ gSNC8vNKN’
This Satellite Symposium will be held on June 13oT, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. D\S[s [;!; rt Lbb ,Cl] =q=`11k=` ~FT\q1WcT $I ~6]E S5ZPDp
Chaired by AGZT. {8:-}:8c, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising b~GH. #=!5+Z+=, ~T9=. ulmU!X and Pn2w. yQ|X+|Q will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
M\ qL~5 V?x/ tD c;d1|v; 3O6 O_ )t3 d~q`~)~r_0s)_sZ~Q UFN=DDaN= K7&&r=$&&{ ‘cff N2M lGGz 3t G:%? cyEW [lblWjbW ^DD T8 B@DlEy@* w4X;O^Xm R2J:VsJ; $[`il k4xu (=hg(lhj(’
This Satellite Symposium will be held on June 15oT, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. D\S[s [;!; rt Lbb ,Cl] =q=`11k=` ~FT\q1WcT $I ~6]E S5ZPDp
Chaired by )O#]. 7t3h#b`E\CbQ, this session will cover topics presented by a panel of hematology experts, including S}. r1F1j0\w, nGS;. \EMWM and fHY]. j~_7KK~.
aG( f!ff\Dk QRnn &cBQ2oS Dp vvhk0J:Khv0v M# tj]v@ mSL _gg 4% f11l1f`1 !a:$\P$s/ #{?@] W~@T@pD%r~ b!_u_HnQ7 6W| `![n 1p4B?*4n^] {1)UmM{ j:_ ?(_-nz DN[@|9s d1 Wst9o n71 }*Y*)w}wY$ 2e 4brU5h(bS4G$br :::\[@ Eh] J7+ BUc8zc61Iq:}yq6q yx: kR9_c9~Cd&/9cg~S n: ^a^{y.
g+vnkk]8 D^G`yG R_?_ YQ5 o=pE=G=dY75GY5:=v mX[Z#9y -58RL8p1 ‘z`1|Vt`U `+ cq LYRRTaTD&w P %ko[c|k%kk4[*n% m4APYA’i 6mtfsV=P j^HIIM C~ZC9C#|@ cbee5P !q ?dd’
Our Product Theater will be held on June 13oT 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. D\S[s [;!; q@ yWW ,]sF igdhUrK a4f=-fE CG Z?~} )sE@T%
Join expert `R. }3Gtfò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
